daily oral glp-1 receptor agonist orforglipron for adults with obesity Pill Approved by FDA Oral GLP-1 Pills for Weight

During this stage, 300 articles were excluded due to irrelevance to the research question or failure to meet the inclusion criteria (22 clinical trials, 43 reviews or other unfitting literature, 112 wrong cell type, 49 wrong focus, 10 wrong drugs, 57 in vivo, 2 retractions, 3 no abstract and 2 not peer reviewed yet)

Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKC activation in diabetes

Dong, Y

& Gardner, D

Notably, while GLP-1 can potentially affect glucagon secretion via its stimulatory effect on the -cells in normal physiological conditions, GLP-1 also inhibits glucagon release in type 1 diabetes, thus demonstrating that GLP-1 inhibition of glucagon secretion does not fully depend on the -cell secretome [516]